Skip to main content

Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas: An Open-Label Series

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Background.

Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment. Objective.

To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC. Results.

After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor. Conclusion.

Imiquimod 5% cream may be another treatment modality for nodular BCC.

DRS. RAYMOND T. KUWAHARA, RAASHID HAQUE, AND ROBERT B. SKINNER, JR. ARE CONSULTANTS FOR 3M PHARMACEUTICALS.

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1524-4725.2004.30116.x

Affiliations: 1: Department of Medicine, Division of Dermatology, University of Tennessee, 2: Memphis Dermatology Clinic, Memphis, Tennessee, and

Publication date: 2004-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more